Prodesse's ProFlu+ Test for Respiratory Viruses receives FDA clearance

Prodesse, Inc., the leader in multiplex real-time PCR for infectious disease, announced that it received clearance from the U.S. Food and Drug Administration (FDA) to market its ProFlu+™ Assay.

The ProFlu+ test provides results in as few as three hours. Other diagnostic tests for respiratory viruses are fast but not as accurate or are accurate but not as rapid.

The real-time test employs a multiplex platform that allows several tests to be processed using the same sample to detect influenza A virus, influenza B virus, and respiratory syncytial virus A and B (RSV).

These viruses can cause influenza, an infection of the airways called bronchiolitis, and pneumonia. All are among the leading causes of lower respiratory tract infections.

"Antiviral drugs are most effective when initiated within the first two days of symptoms," said Daniel Schultz, M.D., director of FDA's Center for Devices and Radiological Health. "This new test, which is part of the new era of molecular medicine, can help the medical community quickly determine whether a respiratory illness is caused by one of these four viruses and initiate the appropriate treatment."

ProFlu+ uses a molecular biology process to isolate and amplify viral genetic material present in secretions taken from the back of the throat in patients.

While ProFlu+ is faster than conventional tests, it is specific to the four viruses, and is more accurate when used with other diagnostics, such as patient data, bacterial, or viral cultures, and X-rays, in diagnosing a patient. Positive results do not rule out other infection or co-infection and the virus detected may not be the specific cause of the disease or patient symptoms.

An estimated 5 percent to 20 percent of the U.S. population contracts influenza each year, resulting in more than 200,000 hospitalizations and up to 36,000 deaths. Influenza A, one of three types of human influenza, is the most severe and has been the cause of major epidemics. Influenza B is less severe than influenza A.

Bronchiolitis usually affects children under the age of 2, and is a common, sometimes severe illness. A common cause of the disease is RSV.

Pneumonia is a common illness that affects millions of people each year in the United States and is usually caused by an infection. People most at risk are older than 65 or younger than 2 years of age, or already have health problems.

ProFlu+ is manufactured by Prodesse, Inc. of Milwaukee.

(Published at Health News Track on January 20, 2008 - 352 days ago)

Diagnosis article/news source:

Prodesse - read other health news articles from Prodesse and health news articles from USA.

Diagnosis - related articles/news stories:

- Brain maps to assist disease diagnosis, brain surgery
- Progress in TB diagnosis and control slowing
- Laser to detect potential diseases via breath
- New test to detect and identify 12 respiratory viruses


»» NEJM Antidepressant's Publication study may discourage depressed people
«« Intelence, etravirine HIV Drug approved in US

The information provided on Health Newstrack is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.
We comply with the HONcode principles for trustworthy health information, verify here.
www.healthnewstrack.com - About us, Editorial team, Advertising, Jobs, Links, Privacy policy, Disclaimer, Feedback,
Site map, List health news, Health news organizations, Health news world, Accessibility, Glossary, Testimonials, Blog
Mobile/PDA Submit press release
© 2007-2008 HealthNewstrack.com
Track Health News Daily
1.67